Blocking connexin hemichannels to protect muscles after nerve or muscle injury
Official title: Connexin Hemichannel Blockers to Preserve Muscle Function and Improve Recovery After Neuromuscular Trauma
Funded at Philadelphia VA Medical Center · NIH-11220432 · Data updated 2026-11-12
An oral drug called boldine is being used to try to protect muscles and improve recovery for people with severe nerve or muscle injuries.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Philadelphia VA Medical Center NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | November 1, 2024 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| NIH project number | 5I01RX005045-02 |
| Project ID | NIH-11220432 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who recently suffered severe peripheral nerve or muscle injuries and who may face delayed surgical repair would be the eventual candidates for this approach.
✕Less likely to help
People with very long-standing denervation, fixed contractures, or long-term chronic muscle loss are unlikely to benefit from this treatment.
What this research studies
This project uses boldine, a pill that blocks connexin hemichannels, to try to slow muscle wasting after denervation from nerve or muscle trauma. Researchers will perform detailed lab and molecular studies and then test the treatment in established rodent and pig injury models to see if muscles stay healthier and reinnervate better. The team will measure genes, proteins, and muscle function to understand how the drug works and whether it improves recovery. Successful results would support moving this approach toward human trials for people with peripheral nerve or muscular injuries.
Why it matters
Potential benefit: If successful, this approach could extend the time window for nerve repair, reduce muscle atrophy, and increase the chance of regaining strength and movement.
How similar studies have gone: This is largely a novel, preclinical approach: some laboratory studies suggest connexin blockers can protect muscle, but human benefit has not been demonstrated.
Where this research is happening
-
Philadelphia VA Medical Center
Philadelphia, United States Active
Researchers
- Principal investigator: Cullen, Daniel Kacy — Philadelphia VA Medical Center
- Study coordinator: Cullen, Daniel Kacy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.